Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06905587 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue

Study acronym: EMBRAIN
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 1 of 4 sitesv4
  2. Site details revised at 1 of 4 sitesv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2025 to Sep 2, 2025
    • Site details revised at 4 of 4 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking. The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD). If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.
Trial Details
NCT Number NCT06905587
Lead Sponsor Odense University Hospital
Collaborators: Aarhus University Hospital Skejby, Aalborg University Hospital, Rigshospitalet, Denmark, University of Southern Denmark
Conditions
(from sponsor)		 Brain Tumor, Pediatric, Cancer-related Fatigue, Methylphenidate
Related terms Brain Neoplasms, Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov